- Home
- REVG vs SUPN Comparison
REVG vs SUPN Comparison
Compare REVG & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REVG
- SUPN
- Stock Information
- Founded
- REVG 2008
- SUPN 2005
- Country
- REVG United States
- SUPN United States
- Employees
- REVG N/A
- SUPN N/A
- Industry
- REVG Auto Manufacturing
- SUPN Biotechnology: Pharmaceutical Preparations
- Sector
- REVG Consumer Discretionary
- SUPN Health Care
- Exchange
- REVG Nasdaq
- SUPN Nasdaq
- Market Cap
- REVG 1.8B
- SUPN 2.1B
- IPO Year
- REVG 2017
- SUPN 2012
- Fundamental
- Price
- REVG $31.35
- SUPN $33.05
- Analyst Decision
- REVG Hold
- SUPN Hold
- Analyst Count
- REVG 4
- SUPN 2
- Target Price
- REVG $33.75
- SUPN $36.00
- AVG Volume (30 Days)
- REVG 500.6K
- SUPN 464.2K
- Earning Date
- REVG 03-05-2025
- SUPN 02-25-2025
- Dividend Yield
- REVG 0.76%
- SUPN N/A
- EPS Growth
- REVG 512.99
- SUPN 130.79
- EPS
- REVG 4.72
- SUPN 1.07
- Revenue
- REVG $2,380,200,000.00
- SUPN $651,972,000.00
- Revenue This Year
- REVG $0.75
- SUPN $7.94
- Revenue Next Year
- REVG $6.92
- SUPN N/A
- P/E Ratio
- REVG $6.66
- SUPN $31.70
- Revenue Growth
- REVG N/A
- SUPN 6.79
- 52 Week Low
- REVG $17.76
- SUPN $25.53
- 52 Week High
- REVG $36.00
- SUPN $40.28
- Technical
- Relative Strength Index (RSI)
- REVG 39.33
- SUPN 32.98
- Support Level
- REVG $32.01
- SUPN $32.53
- Resistance Level
- REVG $34.27
- SUPN $39.99
- Average True Range (ATR)
- REVG 1.24
- SUPN 1.31
- MACD
- REVG -0.25
- SUPN -0.69
- Stochastic Oscillator
- REVG 8.73
- SUPN 6.71
About REVG REV Group Inc.
REV Group Inc is a United States-based designer, manufacturer, and distributor of specialty vehicles and related aftermarket parts and services. During the first fiscal quarter of 2024, the Company formed the Specialty Vehicles Segment by combining the Fire & Emergency and Commercial segment businesses. Additionally, the Recreation segment was renamed Recreational Vehicles. As a result, the Company is now organized into two reportable segments. The company operates in the United States, Canada, and the rest of the world. Maximum of revenue is gained from Specialty Vehicles Segment.
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.